Rigel Pharmaceuticals Inc (RIGL)
Rigel Pharmaceuticals Inc. is a biotechnology company listed on NASDAQ under the ticker RIGL. The company focuses on therapies for hematologic disorders and cancer, with operations in the United States. Its marketed products include TAVALISSE for adult patients with chronic immune thrombocytopenia, REZLIDHIA for certain adults with relapsed or refractory acute myeloid leukemia carrying an IDH1 mutation, and GAVRETO for selected patients with RET fusion-positive non-small cell lung cancer and advanced or metastatic RET fusion-positive thyroid cancer. Rigel is also advancing R289, an oral IRAK1/4 inhibitor in early-stage clinical development across hematology-oncology, autoimmune, and inflammatory indications, including lower-risk myelodysplastic syndrome. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center and the CONNECT clinical trial network.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RIGL
|
$49.52
|
25.1% Upside
|
Undervalued
|
$54.20
|
37.0% Upside
|
Undervalued
|
Excellent
|
—
|
—
|
—
|
0.0%
|
August 4, 2026
|
2.0x
|
1.8x
|
2.4x
|
734 M
|
619.5 M
|
5.9%
|
86.1%
|
3.1
|
—
|
21.8%
|
